CDK6 has been more frequently involved in the progression of hematological malignancy being altered in leukemia, lymphoma, and B-lymphoid malignancies due to chromosomal translocation involving the 7q21 locus and as critical a mediator of Notch signaling in T-cell acute lymphoblastic leukemia (T-ALL) and in MLL-rearranged leukemias, where it blocks myeloid differentiation.328,329 It is also hyperactivated or rearranged in various malignancies, including sarcoma, melanoma, breast cancer, glioma, and medulloblastoma.330,331. This evidence concerns the gene CDK6 and acute lymphoblastic leukemia.